학술논문
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Document Type
Article
Author
Source
In The Lancet 10-16 July 2021 398(10295):143-155
Subject
Language
ISSN
0140-6736